慢性肾衰竭合并结核病在抗结核治疗中药动学的研究进展  

Research Progress of Anti-tuberculosis Medicine Dynamics in the Treatment of Chronic Renal Failure Complicated with Tuberculosis

作　　者：范立萍[1] 姚晶瑞[1] 易丽萍[1] 张悦凤[1] 

机构地区：[1]天津市海河医院透析室,天津300350

出　　处：《医学综述》2013年第21期3894-3897,共4页Medical Recapitulate

基　　金：天津市卫生局资助课题(09KZ37)

摘　　要：在免疫功能低下患者中常常发生结核杆菌感染,如慢性肾衰竭。抗结核药物在肾功能不全患者中的药动学及剂量调整是非常重要的,在肾功能不全的患者中,尤其是透析患者应更加重视。抗结核药物在透析一段时间后通常被透析清除一部分,需要随时调整剂量。然而,在肾衰竭的患者中对这些药物的剂量调节仍需进一步的药动学研究,特别是血液透析对于药动学的影响。Mycobacterium tuberculosis infection often occurs in irnmunocompromised patients, such as chronic renal failure. Pharmacokinetics and dose adjustment of anti-tuberculosis drugs in patients with renal failure patients is very important, especially in dialysis patients. Antituberculosis drugs are usually partly removed after a period of dialysis, and the dosage needs to be adjusted whenever necessary. However, further pharmacokinetic studies in renal failure patients, especially the effect of hemodialysis for pharmacokinetics are still needed for the adjustment of the dosage.

关 键 词：慢性肾衰竭 结核病 抗结核药 药动学 

分 类 号：R692.5[医药卫生—泌尿科学]